

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Philip S. Kim M.D.

Confirmation No.: 9491

Application No.: 10/616,247

Group Art Unit: 3763

Filing Date: July 9, 2003

Examiner: Stigell, Theodore J.

For: Selective Peripheral Nerve Plexus Implantable Infusion Device and Method

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Electronic Filing
I hereby certify that this paper (along with any referenced attachments) is being transmitted
via the USPTO electronic filing system in accordance with 37 CFR § 1.6(a)(4).

Dated: December 6, 2007

Signature: *Jeannette Rayfield*
Jeannette Rayfield

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR §1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above-identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under §1.114, no additional fee is required.

☒ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☒ The fee of \$180.00 as set forth in §1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after

the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in §1.17(p).

☒ A copy of reference number **25** listed on the attached Form PTO/SB/08a is enclosed herewith.

☐ Copies of reference numbers ____ **through** ____ on the attached Form PTO/SB/08a are not required to be submitted pursuant to 37 CFR §1.98(a)(2)(i).


☐ Copies of references ____ are not being submitted because they were previously cited by or submitted to the US Patent and Trademark Office in patent application numbers ____ filed ____ for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

☐ The relevance of those listed references which are not in the English language () is as follows: _____ Patent No. _____, which was cited in the _____ Search Report (a copy of which is attached)

☒ There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. **02-2555**.

Date: December 5, 2007



Bruce D. George
Registration No. 43,631

Blank Rome LLP
Correspondence Customer Number: **64574**
One Logan Square
130 North 18th Street
Philadelphia, PA 19103
Telephone No. (215) 569-5798
Facsimile No. (215) 832-5798